FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks
Portfolio Pulse from Vandana Singh
The FDA has placed a clinical hold on vTv Therapeutics' (NASDAQ:VTVT) cadisegliatin program, including the ongoing CATT1 Phase 3 trial for type 1 diabetes, due to an unresolved chromatographic signal in a recent study. This has caused VTVT stock to drop by 32.2%.
July 29, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA has placed a clinical hold on vTv Therapeutics' cadisegliatin program, including the ongoing CATT1 Phase 3 trial for type 1 diabetes, due to an unresolved chromatographic signal in a recent study. This has caused VTVT stock to drop by 32.2%.
The clinical hold by the FDA on vTv Therapeutics' cadisegliatin program is a significant regulatory setback, directly impacting the company's primary product development. This has led to a substantial drop in the stock price, reflecting investor concerns.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100